as 12-13-2024 4:00pm EST
Stocks
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 30.9M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 66.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.01 | EPS Growth: | N/A |
52 Week Low/High: | $1.98 - $4.97 | Next Earning Date: | 12-24-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GRCE Breaking Stock News: Dive into GRCE Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
3 days ago
GlobeNewswire
10 days ago
Zacks Small Cap Research
a month ago
Simply Wall St.
a month ago
GlobeNewswire
a month ago
Zacks Small Cap Research
a month ago
GlobeNewswire
a month ago
The information presented on this page, "GRCE GRACE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.